Results 31 to 40 of about 89,996 (262)
Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis
Diagram of the activation of the profibrotic and procontractile Janus kinase 2 (JAK2)/Ras homolog family member A/Rho‐kinase pathway and the inhibition of phosphorylated JAK2 by pacritinib to inhibit hepatic stellate cell activity. Abstract Background and Aims Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with ...
Sandra Torres +21 more
wiley +1 more source
The intestinal microbiome and the leaky gut as therapeutic targets in alcoholic liver disease
Alcoholic liver disease (ALD) encompasses hepatic steatosis, which may progress to alcoholic hepatitis, fibrosis, and cirrhosis. It remains a leading cause of morbidity and mortality in the US and worldwide.
Phillipp eHartmann +2 more
doaj +1 more source
Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis
Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis. Abstract Background and Aims Nucleotide‐binding oligomerization domain‐like receptor‐family pyrin domain‐containing 3 (NLRP3) inflammasome activation has been shown to result in liver fibrosis.
Jana Knorr +19 more
wiley +1 more source
Background & Aims: Excessive alcohol consumption accelerates fibrosis progression in steatotic liver disease. Disease activity can be described by fibrogenic activity, of which collagen formation is a central process. Type III collagen formation (PRO-
Stine Johansen +14 more
doaj +1 more source
Non-alcoholic steatohepatitis (NASH) is a major cause of chronic liver disease. However, most available animal models fail to reflect the whole spectrum of the disease.
Raquel Maeso-Díaz +6 more
doaj +1 more source
NRPT 1X reduces ALT and ceramide 14:0 in 65% of subjects as compared to only 28% in the placebo group. Abstract Background and Aims The prevalence of NAFLD is increasing globally and on a path to becoming the most frequent cause of chronic liver disease. Strategies for the prevention and treatment of NAFLD are urgently needed.
Ryan W. Dellinger +7 more
wiley +1 more source
Non-invasive tests for MetALD and alcohol-related liver diseaseKeypoints
Summary: Metabolic- and alcohol-related liver disease (MetALD) and alcohol-related liver disease (ALD) are major drivers of the global burden of cirrhosis. While metabolic dysfunction-associated steatotic liver disease (MASLD) affects nearly one-third of
Stine Johansen +2 more
doaj +1 more source
Evaluating the effect of γ‐oryzanol on MASLD pathology using a medaka fish model
This study explores a liver disease called MASLD, which is increasing worldwide and can lead to serious damage. Researchers used medaka fish instead of rodents to test a food compound, γ‐oryzanol. Fish fed this compound had less liver fat and healthier gut bacteria.
Yukako Ito +7 more
wiley +1 more source
CD11b+CD43hiLy6Clo splenocyte‐derived macrophages exacerbate liver fibrosis via spleen–liver axis
A population of splenic monocytes migrate into the liver and shift to macrophages, which account for the exacerbation of liver fibrosis. Abstract Background and Aims Monocyte‐derived macrophages (MoMFs), a dominant population of hepatic macrophages under inflammation, play a crucial role in liver fibrosis progression.
Shaoying Zhang +18 more
wiley +1 more source
Background & Aims: Infections are frequent in patients with cirrhosis and worsen prognosis. We evaluated the incidence of infections and their impact on decompensation and death in patients with early alcohol-related liver disease (ALD) during long ...
Stine Johansen +33 more
doaj +1 more source

